T1542

Pirenzepine dihydrochloride (LS519) is a selective M1 muscarinic receptor antagonist, inhibiting gastric secretion.

GS-9901 is a selective, orally active and potent PI3Kδ inhibitor (IC50: 1 nM) for the study of non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

GSK-626616 is a potent and orally bioavailable DYRK3 inhibitor (IC50: 0.7 nM). It inhibits other members of the DYRK family with similar potency. GSK-626616 is a potential therapy for the treatment of anemia.

GSK-269984A is an antagonist of Prostaglandin E2 Receptor 1 (EP1) (pIC50: 7.9).

GSK-7975A is a potent, orally available inhibitor of the Calcium Release-Activated Calcium (CRAC) channel.

GSK1702934A, a selective TRPC3 agonist, modulates cardiac contractility and arrhythmogenesis through TRPC3 activation.

GSK180 is a selective, competitive, and highly potent inhibitor of kynurenine-3-monooxygenase (KMO), a critical enzyme in the tryptophan metabolic pathway, with an IC50 value of approximately 6 nM, displaying minimal off-target activity against other tryptophan pathway enzymes, rapidly altering kynurenine metabolite profiles, GSK180 serves as a powerful research tool for probing the biological and therapeutic implications of KMO inhibition in metabolic, neurological, and inflammatory disease models.

GSK2033 is an antagonist of LXR (pIC50s: 7 and 7.4 for LXRα or LXRβ, respectively).

Uprosertib hydrochloride is a potent and selective inhibitor of pan-Akt (IC50: 180/328/38 nM for Akt1/Akt2/Akt3, respectively).

GSK2194069 is an active β-keto reductase (KR)-specific inhibitor of fatty acid synthase (FASN) with an IC50 of 7.7 nM in an assay for the detection of released CoA.GSK2194069 inhibits the proliferation of FAS in cancer cells through the action of acetoacetyl-coenzyme A and NADPH.